TY - JOUR AU - Ocadlikova, Darina AU - Lecciso, Mariangela AU - Broto, Javier Martin AU - Scotlandi, Katia AU - Cavo, Michele AU - Curti, Antonio AU - Palmerini, Emanuela PY - 2021 DO - 10.3389/fimmu.2021.577766 UR - http://hdl.handle.net/10668/17350 T2 - Frontiers in immunology AB - High-grade sarcomas are a heterogeneous group of aggressive tumors arising in bone and soft tissues. After relapse, treatment options are limited. The multi-targeted receptor tyrosine kinase inhibitors (TKIs) sunitinib and inhibitor of PD-1... LA - en KW - T regulatory cells (Tregs) KW - dendritic cell (DC) KW - immunomodulation KW - nivolumab (PubChem SID: 178103907) KW - osteosarcoma KW - sunitinib (PubChem CID: 5329102) KW - synovial sarcoma KW - tyrosine kinase inhibitor (TKI) KW - Apoptosis KW - Biomarkers KW - Cell Line, Tumor KW - Cell Proliferation KW - Dendritic Cells KW - Humans KW - Immune Checkpoint Inhibitors KW - Immunomodulation KW - Immunophenotyping KW - Interferon-gamma KW - Lymphocyte Activation KW - Programmed Cell Death 1 Receptor KW - Protein Kinase Inhibitors KW - Sunitinib KW - T-Lymphocyte Subsets KW - T-Lymphocytes, Regulatory TI - Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. TY - research article VL - 12 ER -